Purchase this article with an account.
E. Peiretti, M. Vinci, M. Fossarello; Long Term Follow- Up in Patients With Choroidal Neovascularization Associated With Pathologic Myopia Treated With Intravitreal Injection of Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2202.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to evaluate in a monocenter, consecutive,non randomized interventional case series of 21 eyes the long-term efficacy of intravitreal injection of bevacizumab (Avastin) in patients with choroidal neovascularization (CNV) associated with pathologic myopia (PM).
retrospective study on a group of 21 eyes of 21 patients (mean age 59 yrs) with CNV associated with PM (mean - 12 diopters ,+/- -5) were treated with at least 2 intravitreal injections of 1.25 mg/0.05 ml bevacizumab. Four patients were treated with verteporfin PDT before bevacizumab injection. Patients underwent a complete ophthalmological examination at baseline and at follow-up visits, including Snellen visual acuity (VA) testing, optical coherence tomography (OCT), fluorescein (FA) and indocyanine green (ICG) retinal angiography. The median follow-up was 30,9 months (DS 6,15) in a range between 25 and 42 months. The patients who showed recurrence of the lesion, as assessed by FA, OCT and visual symptoms were retreated for a maximum of 15 injections. No side effects were observed in our series.
pre-treatment mean best corrected (BC) VA was logMAR 0,67± 0,43. At 1 year follow-up, mean BCVA was logMAR 0,51 ±0,39 and at the end of follow up the VA was logMAR 0,57±0,45. At minimum follow up of 25 months, 61,9% (13eyes) of patients demonstrated an improvement of VA from 1 to 3 Snellen lines. 23,8% (5 eyes)of patients showed stabilizations of VA acuity with minimal amount of subretinal fluid, as assessed by OCT examination and the remaining patients 14,3%(3 patients). No significant ocular or systemic side effects were observed in our patients after bevacizumab injection.
on the basis of our preliminary data, intravitreal injection of bevacizumab should be considered as effective treatment for patients with CNV associated with PM.
This PDF is available to Subscribers Only